In a collaborative study, ISD researchers found that Alpha-synuclein co-pathology is more common in advanced AD and accelerates tau aggregation and cognitive decline. This underscores the need to consider αSyn in AD research and treatment strategies, particularly in amyloid-driven tau pathophysiology.